Chu DK, et al. - As aspirin desensitization is increasingly recommended to treat aspirin-exacerbated respiratory disease (AERD), researchers conducted this systematic review to test the safety and efficacy of aspirin desensitization (mean daily dose 800 mg) in patients (n = 233) with AERD. From inception to January 5, 2019, MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and World Health Organization (WHO) International Clinical Trials Registry Platform were searched. According to findings, moderate-certainty and high-certainty evidence in patients with AERD indicates that aspirin desensitization meaningfully decreases symptoms of rhinosinusitis and improves quality of life, but results in a significant increase in adverse events like major bleeding, gastritis, asthma exacerbation, or rash causing drug discontinuation.